ISAKOS: 2023 Congress in Boston, MA USA

2023 ISAKOS Biennial Congress ePoster

 

Effectiveness Of Intra-Articular Injection Of Platelet-Derived Extracellular Vesicles For Treating Patients With Mild Or Moderate Knee Osteoarthritis

Jonas Fernandez, MD, Ms Orth, kuala lumpur, Kuala Lumpur MALAYSIA
University Malaya Medical Centre, kuala lumpur, Kuala Lumpur, MALAYSIA

FDA Status Not Applicable

Summary

Comparing the efficacy of intra-articular injection treatment options, patients treated with PEV showed the best improvement in most subscales

ePosters will be available shortly before Congress

Abstract

58 patients with Kellgren-Lawrence grades I-III osteoarthritis, normal or overweight BMI and age 55-80 years recruited. PEVs were isolated from autologous blood specimens using density gradient centrifugation in our accredited Good Manufacturing Practice(GMP) laboratory (N=17). Vesicle sizes of PEVs were characterized using transmission electron microscope. However, patients in HA group(N=20) underwent intraarticular knee injection using Hyruan One which was provided by the Life’s Good company(Korea). Control group(N=21) treated conservatively. The KOOS, WOMAC and SF36v2 questionnaires filled before treatment and one month after. Data obtained from each subscale of the questionnaires were analysed using the SPSS version-23.

No significant differences in the gender, ethnicity, BMI and OA severity between groups. In pre-test survey, groups’ scores were comparable in all subscales, except for KOOS and SF-36v2 pain, whereby the control group showed significant higher scores compared to PEV and HA groups. .

PEV group showed significant improvement after one month in the KOOS pain(P=.000), ADL(P=.001), symptoms(P=.001) and QOL(P=.000), WOMAC stiffness(P=.001) and pain(P=.034), SF-36v2 physical functioning(P=.001), pain(P=.002), physical limitation(P=.002), social functioning(P=.018) and energy(P=.002) subscales.
Comparing the groups in the post-test survey, PEV demonstrated significantly better improvement compared to control and HA groups in the KOOS pain(P=.003), symptoms(P=.044), ADL(P=.001) and QOL, (P=.001) WOMAC pain (P=.008)and SF-36v2 physical function(P=.016) subscales. PEV also showed non-statistically significant improvement in the WOMAC stiffness and SF-36v2 physical limitation subscales. These results are in contrary to study that showed blood products has no superior clinical benefits over.